This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Sanofi's Sarclisa Gets FDA Nod for Third-Line Multiple Myeloma
by Zacks Equity Research
The FDA approves Sanofi's (SNY) Sarclisa (isatuximab) combo for the treatment of adult patients with relapsed refractory multiple myeloma in the third-line setting.
5 Biotechs That Escaped the Coronavirus Onslaught Last Week
by Kinjel Shah
Here we discuss 5 biotech stocks that outperformed the industry amid the U.S. market slump.
These 6 Drug Companies are Testing a Coronavirus Vaccine
by Madeleine Johnson
As the coronavirus outbreak continues to spread, some of the biggest drug companies are moving closer to finding a vaccine.
These 6 Drug Companies are Testing a Coronavirus Vaccine
by Madeleine Johnson
As the coronavirus outbreak continues to spread, some of the biggest drug companies are moving closer to finding a vaccine.
Pharma Stock Roundup: FDA Updates From LLY, GSK, NVS, SNY to Spin-Off API Unit
by Kinjel Shah
FDA accepts Glaxo (GSK) and Novartis' (NVS) sBLA. FDA gives approval to Lilly's (LLY) Trulicity for cardiovascular indication.
Esperion (ESPR) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Esperion Therapeutics (ESPR) reports encouraging fourth-quarter results. The company is set to launch its first drug next month.
BioMarin (BMRN) Q4 Earnings Beat, Sales Miss, Valrox in Focus
by Zacks Equity Research
BioMarin (BMRN) announces mixed results for the fourth quarter of 2019, beating estimates for earnings while missing the same for sales.
Sanofi Plans Spin-Off of API Unit Into a European Company
by Zacks Equity Research
Sanofi (SNY) plans to combine its API commercial activities with six of its European API production sites and spin-off the same into an independent European API company.
BioMarin (BMRN) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Key orphan disease drugs, Vimizim and Kuvan, are likely to have driven BioMarin's (BMRN) fourth-quarter top line.
Emergent (EBS) Earnings Miss in Q4, Revenues Beat Estimates
by Zacks Equity Research
Emergent's (EBS) earnings lag estimates in Q4 while revenues surpass the mark.
Pharma Stock Roundup: AZN Reports Q4 Results, NVS, PFE Drugs Get EU Approval
by Kinjel Shah
AstraZeneca's (AZN) Q4 results were disappointing. European Commission approves Novartis (NVS) and Pfizer's (PFE) new drugs.
What's in the Cards for Amarin (AMRN) This Earnings Season?
by Zacks Equity Research
Amarin's (AMRN) fourth-quarter results are likely to reflect strong demand for its cardiovascular drug, Vascepa.
Sanofi, J&J Join Forces With BARDA for Coronavirus Vaccine
by Zacks Equity Research
Sanofi (SNY) and J&J (JNJ) sign deals with BARDA, part of U.S. Department of Health and Human Services, for accelerated development of a vaccine for the newly found coronavirus.
Top Research Reports for Facebook, Netflix & NextEra Energy
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Facebook (FB), Netflix (NFLX) and NextEra Energy (NEE).
Regeneron Reports Positive Eylea Data From Late-Stage Study
by Zacks Equity Research
Regeneron (REGN) announces positive two-year results from the phase III PANORAMA study on lead ophthalmology drug, Eylea.
Pharma Stock Roundup: BMY, GSK, SNY Q4 Results, MRK Earnings & Split
by Kinjel Shah
Merck (MRK), Bristol Myers (BMY), Sanofi (SNY), Glaxo (GSK) and Novo Nordisk (NVO) announce Q4 results.
Alnylam's (ALNY) Q4 Earnings Miss Estimates, Sales Beat
by Zacks Equity Research
Alnylam (ALNY) posts a wider-than-expected loss, while revenues beat estimates marginally in the fourth quarter of 2019.
Sanofi (SNY) Q4 Earnings Top, Sales Miss, Dupixent Strong
by Zacks Equity Research
Sanofi (SNY) reports mixed fourth-quarter results with strong Specialty Care and Vaccines sales but soft Consumer Healthcare sales
Regeneron's (REGN) Q4 Earnings & Sales Surpass Estimates
by Zacks Equity Research
Regeneron (REGN) beats on Q4 earnings and sales on solid performance of ophthalmology drug, Eylea, and asthma drug, Dupixent.
Novo Nordisk (NVO) Q4 Earnings Match Estimates, Revenues Beat
by Zacks Equity Research
Novo Nordisk (NVO) posts in-line earnings, while revenues beat estimates in the fourth quarter of 2019.
Why Earnings Season Could Be Great for Sanofi (SNY)
by Zacks Equity Research
Sanofi (SNY) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Merck (MRK) Beats on Q4 Earnings, Plans Women Health Spin Off
by Zacks Equity Research
Merck (MRK) beats estimates for earnings but misses the same for sales in fourth-quarter 2019. The company plans to spin off Women Health drugs/biosimilars into new company. Shares down.
Merck's Recarbrio Gets FDA Priority Review for New Indication
by Zacks Equity Research
The FDA accepts Merck's (MRK) sNDA for antibacterial injection Recarbrio and grants priority review.
Will Eylea & Dupixent Drive Regeneron's (REGN) Q4 Earnings?
by Zacks Equity Research
Investors will focus on the performance of Eylea and Dupixent along with other pipeline updates, when Regeneron (REGN) reports fourth-quarter 2019 results.
Lilly's NDA for Selpercatinib Gets FDA's Priority Review
by Zacks Equity Research
Lilly's (LLY) NDA for oral RET inhibitor selpercatinib gains the FDA priority review status for RET-altered lung and thyroid cancers.